These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19048198)

  • 1. Viral protease inhibitors.
    Anderson J; Schiffer C; Lee SK; Swanstrom R
    Handb Exp Pharmacol; 2009; 189(189):85-110. PubMed ID: 19048198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
    Mathy JE; Ma S; Compton T; Lin K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
    Yang H; Bartlam M; Rao Z
    Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral drug discovery targeting to viral proteases.
    Hsu JT; Wang HC; Chen GW; Shih SR
    Curr Pharm Des; 2006; 12(11):1301-14. PubMed ID: 16611117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteases and protease inhibitors in infectious diseases.
    Agbowuro AA; Huston WM; Gamble AB; Tyndall JDA
    Med Res Rev; 2018 Jul; 38(4):1295-1331. PubMed ID: 29149530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting viral proteases: challenges and opportunities.
    Bianchi E; Pessi A
    Biopolymers; 2002; 66(2):101-14. PubMed ID: 12325160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric inhibitors of the NS3 protease from the hepatitis C virus.
    Abian O; Vega S; Sancho J; Velazquez-Campoy A
    PLoS One; 2013; 8(7):e69773. PubMed ID: 23936097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?
    Zhu Z; Wilson AT; Luxon BA; Brown KE; Mathahs MM; Bandyopadhyay S; McCaffrey AP; Schmidt WN
    Hepatology; 2010 Dec; 52(6):1897-905. PubMed ID: 21105106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.